Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization

Ahn, Seong Joon; Park, Kyu Hyung; Woo, Se Joon

doi:10.1167/iovs.14-16006

Cited by 32 publications

(26 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oishi et al reported similar findings after 4 years of bevacizumab treatment; 72.7 % developed or had enlargement of CRA [75]. The relationship between the development of CRA and the number of anti-VEGF injections is unclear,; in a study by Ahn et al subfoveal choroidal thickness was found to be significantly decreased following anti-VEGF therapy which may play a role in eventual development of CRA [89]. Two studies provide conflicting evidence on the effects of anti-VEGF treatments on CRA size and enlargement [87,90].…”

Section: • Unclear Benefit Of Combination Of Anti-vegf Withmentioning

confidence: 85%

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Teo

Lee

Cheung

2016

Drugs

View full text Add to dashboard Cite

Myopic choroidal neovascularization (mCNV) is the second most common form of CNV after age-related macular degeneration (AMD). It is a sight-threatening complication of pathologic myopia (PM) and often affects patients in their working years causing significant impact on quality of life. Previous therapies such as photodynamic therapy with verteporfin have shown limited success. Due to the similarities in pathogenesis of mCNV and AMD CNV, anti-vascular endothelial growth factor therapy (anti-VEGF), which has so far been the mainstay of treatment for AMD CNV, has been shown to be effective in the treatment of mCNV and has become the first-line treatment of choice. This article aims to examine briefly the epidemiology and pathophysiology of mCNV, as well as review the evidence for efficacy, safety, and clinical use of anti-VEGF treatment for mCNV.

show abstract

Section: • Unclear Benefit Of Combination Of Anti-vegf Withmentioning

confidence: 85%

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Teo

Lee

Cheung

2016

Drugs

View full text Add to dashboard Cite

show abstract

“…3,20,21 These theories have subsequently been supported to a certain extent by demonstration of associations between choroidal thinning, measured on OCT, with lacquer cracks and mCNV, independent of axial length or refractive error. 4,6,10,19,22 However, there have been no studies evaluating choroidal vascularity in mCNV. The CVI is a novel tool to quantitatively describe the choroidal vasculature, and is calculated as the proportion of LA to TCA.…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6][7] As anti-VEGF is now the treatment of choice of myopic CNV, 8,9 concerns have been raised as to whether progressive thinning of choroid may develop and lead to long-term visual impairment. 10 There have been few studies describing temporal changes in CT and structure in eyes with mCNV treated with anti-VEGF therapy 10,11 and no studies on changes in choroidal vascularity. Choroidal vascularity can now be indirectly measured using a novel technique to derive the choroidal vascular index (CVI).…”

mentioning

confidence: 99%

Choroidal Structural Changes in Myopic Choroidal Neovascularization After Treatment With Antivascular Endothelial Growth Factor Over 1 Year

Ting

Agrawal

Khandelwal

et al. 2016

Invest. Ophthalmol. Vis. Sci.

View full text Add to dashboard Cite

show abstract

“…1 Recent studies have shown that the thickness of the choroid may be affected in retinal conditions such as diabetic retinopathy, age-related macular degeneration (AMD), vascular occlusive diseases, uveitis, and pachychoroid entities. 2–5 In some conditions, choroidal thickness (CT) may be used as a marker of disease activity or treatment response, although intravitreal pharmacotherapies and laser treatments may cause additional alterations to CT. 6–12 …”

Section: Introductionmentioning

confidence: 99%

Macular Fluid Reduces Reproducibility of Choroidal Thickness Measurements on Enhanced Depth Optical Coherence Tomography

Wong

Vuong

Cunefare

et al. 2017

American Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose To determine if different types of retinal fluid in the central macula affect the reproducibility of choroidal thickness (CT) measurements on enhanced depth imaging optical coherence tomography (EDI-OCT) Design retrospective, reliability analysis Methods EDI-OCT images were obtained and the choroidal-scleral junction was analyzed through semi-automated segmentation. CT was measured at the fovea and averaged across the central 3 mm horizontal segment. Demographic data, central macular thickness and type of fluid present were recorded. Intragrader and intergrader repeatability were assessed using the intraclass correlation coefficient (ICC) and coefficient of repeatability (CR). Results Of 124 eyes analyzed, 60 (48.4%) had diabetic macular edema, 32 (25.8%) had neovascular age-related macular degeneration, and 32 (25.8%) had other causes of fluid. Intergrader ICC (CR) were 0.95 (74.1 μm) and 0.96 (63.9 μm) for subfoveal and average CT, respectively. CR were similar across various causes of retinal fluid, but were worst for subretinal fluid compared to intraretinal or sub-retinal pigment epithelial fluid. CR also worsened with increasing choroidal thickness, but was not affected by retinal thickness. Intragrader repeatability was generally greater than intergrader values, and followed the same trend. Conclusions The presence of macular fluid reduces CT measurement reproducibility, particularly in eyes with subretinal fluid and greater choroidal thickness. A difference of 74.1 μm in subfoveal CT or 63.9 μm in average CT may be necessary to detect true clinical change in eyes with macular fluid.

show abstract

Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization

Abstract: Subfoveal choroidal thicknesss significantly decreased following anti-VEGF therapy in myopic CNV, but showed a subsequent increase in recurrence. Subfoveal choroidal thickness may reflect disease activity and aid decision making regarding retreatment in myopic CNV for recurrent cases.

Cited by 32 publications

References 33 publications

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Management of Myopic Choroidal Neovascularization: Focus on Anti-VEGF Therapy

Choroidal Structural Changes in Myopic Choroidal Neovascularization After Treatment With Antivascular Endothelial Growth Factor Over 1 Year

Macular Fluid Reduces Reproducibility of Choroidal Thickness Measurements on Enhanced Depth Optical Coherence Tomography

Contact Info

Product

Resources

About